SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-062072
Filing Date
2023-03-07
Accepted
2023-03-07 07:07:29
Documents
14
Period of Report
2023-03-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d457628d8k.htm   iXBRL 8-K 24903
2 EX-99.1 d457628dex991.htm EX-99.1 47806
6 GRAPHIC g457628g0307073401158.jpg GRAPHIC 3517
  Complete submission text file 0001193125-23-062072.txt   205671

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20230307.xsd EX-101.SCH 2838
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20230307_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20230307_pre.xml EX-101.PRE 10804
8 EXTRACTED XBRL INSTANCE DOCUMENT d457628d8k_htm.xml XML 3229
Mailing Address 8030 EL RIO STREET HOUSTON TX 77054
Business Address 8030 EL RIO STREET HOUSTON TX 77054 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 23711015
SIC: 2834 Pharmaceutical Preparations